1. Early Breast Cancer Trialists' Collaborative Group, Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012; 379:432–44.
2. Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, et al. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Lancet. 2015; 385:1863–72.
3. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003; 21:1431–9.
Article
4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. Plymouth Meeting, PA: National Comprehensive Cancer Network;2018.
5. Gray R, Bradley R, Braybrooke J, Davies C, Pan H, Peto R, et al. Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: an EBCTCG meta-analysis of 21,000 women in 16 randomised trials. In : San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX, USA. Philadelphia, PA: American Association for Cancer Research;2018.
Article
6. Venturini M, Del Mastro L, Aitini E, Baldini E, Caroti C, Contu A, et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst. 2005; 97:1724–33.
Article
7. Foukakis T, von Minckwitz G, Bengtsson NO, Brandberg Y, Wallberg B, Fornander T, et al. Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer: a randomized clinical trial. JAMA. 2016; 316:1888–96.
8. Cameron D, Morden JP, Canney P, Velikova G, Coleman R, Bartlett J, et al. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2017; 18:929–45.
Article
9. Mobus V, Jackisch C, Luck HJ, du Bois A, Thomssen C, Kuhn W, et al. Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. Ann Oncol. 2018; 29:178–85.
10. Waks AG, Tolaney SM, Galar A, Arnaout A, Porter JB, Marty FM, et al. Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. Breast Cancer Res Treat. 2015; 154:359–67.
Article
11. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol. 2009; 27:3540–6.
Article
12. Hasegawa Y, Kawaguchi T, Kubo A, Ando M, Shiraishi J, Isa S, et al. Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials. J Thorac Oncol. 2011; 6:1881–8.
Article
13. Wang Y, Choueiri TK, Lee JL, Tan MH, Rha SY, North SA, et al. Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients. Br J Cancer. 2014; 110:1433–7.
Article
14. Huang RS, Kistner EO, Bleibel WK, Shukla SJ, Dolan ME. Effect of population and gender on chemotherapeutic agentinduced cytotoxicity. Mol Cancer Ther. 2007; 6:31–6.
Article
15. Kim CG, Sohn J, Chon H, Kim JH, Heo SJ, Cho H, et al. Incidence of febrile neutropenia in Korean female breast cancer patients receiving preoperative or postoperative doxorubicin/cyclophosphamide followed by docetaxel chemotherapy. J Breast Cancer. 2016; 19:76–82.
Article
16. Hong J, Lee B, Kang K, Lee SH, Ryu J, Jung G, et al. Characterisation of the site-specific monoPEGylated rhG-CSF analogue pegteograstim. Biologicals. 2018; 51:54–61.
Article
17. Shin KH, Lim KS, Lee H, Jang IJ, Yu KS. An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects. Invest New Drugs. 2014; 32:636–43.
Article
18. Lee KH, Kim JY, Lee MH, Han HS, Lim JH, Park KU, et al. A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09. Support Care Cancer. 2016; 24:1709–17.
Article
19. Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, et al. Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat. 2015; 151:251–9.
Article